LL

Lily Li

Director at Northpond Ventures

San Diego, California

Overview 

Lily Li is a Director at Northpond Ventures in San Diego, California, with a background in lifesciences, market research, and business strategy. She has served on the boards of multiple biotech companies and has made strategic investments in companies like Ansa Biotechnologies and Personal Genome Diagnostics. Highlights of Lily's career include her role as Director at Northpond Ventures, where she leverages her expertise in lifesciences and business strategy to drive growth strategies and investments in innovative companies, and her involvement in the boards of various biotech companies, contributing to their strategic direction and success.

Work Experience 

  • Director

    2023 - Current

    Northpond Ventures is a multi-billion-dollar science-driven venture capital firm based in Cambridge, MA; San Francisco, CA; and Bethesda, MD. Northpond has consistently been named one of the most active lead life science investors in venture industry rankings. It is deeply engaged in the academic ecosystem, having founded The Laboratory for Bioengineering Research and Innovation at the Wyss Institute at Harvard University; launched the MIT-Northpond Program – Advancing Life Science & Engineering Innovation; launched the Northpond Laboratories — Program for Research and Innovation at Stanford Medicine; and sponsored a prize for women entrepreneurs at MIT. It has led or co-led over 60 financings over the past several years and sits on the board of the vast majority of these businesses. Learn more at npv.vc. Current and former board member at: Ansa, 1859, SpeeDx, Vestaron, PGDx (acquired by LabCorp) Current board observer at: Emulate, Encodia, Delfi, Chromacode

  • Principal

    2020 - 2023

Northpond Ventures is a private equity and venture capital that focuses on science-driven projects in life sciences and technology.

  • Member Board of Directors

    2024

  • Member Board of Directors

    2022

Ansa Biotechnologies develops a novel DNA synthesis technology based on enzymes.

Raised $83,419,682.00 from Humboldt Fund, RA Capital Management, Fifty Years, Peak 6, Altitude Life Science Ventures, Fiscus Ventures, Northpond Ventures, Horizons Ventures, Mubadala Capital Ventures and Carbon Silicon Ventures.

  • Member Board of Directors

    2021

  • Member Board of Directors

    2021

  • Board Observer

    2021

Emulate creates advanced in vitro models for understanding how diseases, medicines, chemicals, and foods affect human health.

Raised $271,339,991.00 from Qiming Venture Partners.

  • Board Observer

    2021

Delfi Diagnostics detects cancer early, when it is most curable, using high precision non-invasive blood tests.

Raised $330,500,000.00 from PTX Capital, Northpond Ventures, OUP (Osage University Partners), Brown Advisory, Cowen Healthcare Investments, Foresite Capital, Point Field Partners, OrbiMed, Rock Springs Capital and T. Rowe Price.

  • Board Observer

    2021

Encodia is a biotech company that develops the next generation of protein analysis tools.

Raised $75,000,000.00 from ARCH Venture Partners, Northpond Ventures, Decheng Capital, Google Ventures, Biomatics Capital Partners, Nan Fung Life Sciences, Deerfield, Alexandria Venture Investments and Tao Capital Partners.

  • Board Observer

    2021

ChromaCode is a molecular diagnostics company focusing on bioinformatics.

Raised $93,967,513.00 from Global Brain Corporation.

  • Board Observer

    2021 - 2023

Ultivue is a biotechnology company that specializes in tissue imaging, diagnostics, and multiplexing.

Raised $110,576,238.00 from Northpond Ventures, Applied Ventures, Tao Capital Partners, Ally Bridge Group, Pura Vida Investments and ARCH Venture Partners.

Articles About Lily

Relevant Websites